Edaravone in the Treatment of Aquaporin-4 Antibody-positive Optic Neuritis
Status:
Recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
Edaravone showed a good effect on promoting remyelination and protecting axons in NMOSD
animals. We hypothesize that edaravone can inhibit axonal damage in patients with aquaporin-4
Antibody-positive Optic Neuritis.
Phase:
N/A
Details
Lead Sponsor:
First Affiliated Hospital of Guangxi Medical University